COMBAT: A Phase I/IIa theranostic study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPR-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with ¿¿¿Lu-PSMA-617
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Clarity Pharmaceuticals Pty Ltd (Clarity Pharmaceuticals)
Start Date
September 24, 2024
End Date
October 17, 2029
Administered By
Duke Cancer Institute
Awarded By
Clarity Pharmaceuticals Pty Ltd (Clarity Pharmaceuticals)
Start Date
September 24, 2024
End Date
October 17, 2029